Evelhoch J L, Keller N A, Corbett T H
Cancer Res. 1987 Jul 1;47(13):3396-401.
The in vivo phosphorus-31 nuclear magnetic resonance (NMR) spectra of Adriamycin (ADR)-sensitive murine mammary adenocarcinomas (17/A) and an ADR-resistant subline of this tumor which has been isolated in vivo (17/A/ADR) were compared both before and after i.v. administration of 12 mg/kg ADR. Significant differences between ADR-sensitive and -resistant tumors for the changes observed 1 day after treatment (prior to significant decreases in tumor size) included: the pH increased to greater than 7.3 in response to treatment (or pH remained elevated) in ADR-sensitive tumors only; the inorganic phosphate to nucleoside triphosphates peak height ratio decreased to less than 1 in response to treatment only in ADR-sensitive tumors; glycerophosphocholine to nucleoside triphosphates peak height ratio decreased in response to treatment in ADR-sensitive tumors only; and the phosphocholine to nucleoside triphosphates peak height ratio decreased in response to treatment in ADR-sensitive tumors only. These differences are evidence in support of the hypothesis that in vivo 31P-NMR provides response-specific markers of ADR sensitivity. Because 31P-NMR can be applied to humans, these differences may be of prognostic value in the clinical management of human breast cancer if they are present after treatment with lower, nontoxic doses of ADR.
比较了阿霉素（ADR）敏感的小鼠乳腺腺癌（17/A）及其在体内分离出的ADR耐药亚系（17/A/ADR）在静脉注射12mg/kg ADR前后的体内磷-31核磁共振（NMR）谱。治疗后1天（肿瘤大小显著减小之前）观察到的ADR敏感和耐药肿瘤之间的显著差异包括：仅在ADR敏感肿瘤中，治疗后pH升高至大于7.3（或pH保持升高）；仅在ADR敏感肿瘤中，治疗后无机磷酸盐与核苷三磷酸的峰高比降至小于1；仅在ADR敏感肿瘤中，治疗后甘油磷酸胆碱与核苷三磷酸的峰高比降低；以及仅在ADR敏感肿瘤中，治疗后磷酸胆碱与核苷三磷酸的峰高比降低。这些差异支持了体内31P-NMR提供ADR敏感性的反应特异性标志物这一假设。由于31P-NMR可应用于人类，如果在使用较低的无毒剂量ADR治疗后出现这些差异，它们可能对人类乳腺癌的临床管理具有预后价值。
